Amyris, Inc. (NASDAQ:AMRS) Set to Announce Quarterly Earnings on Thursday
Amyris, Inc. (NASDAQ:AMRS) is set to issue its quarterly earnings data after the market closes on Thursday, August 10th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($1.95) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by $0.60. The firm had revenue of $13 million during the quarter, compared to analysts’ expectations of $32.30 million. Amyris’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the firm earned ($2.55) earnings per share. On average, analysts expect Amyris to post $-3.98 EPS for the current fiscal year and $-1.63 EPS for the next fiscal year.
Amyris, Inc. (NASDAQ AMRS) traded down 2.04% during mid-day trading on Thursday, hitting $3.85. The stock had a trading volume of 484,705 shares. The stock’s market cap is $79.92 million. The firm has a 50-day moving average of $3.47 and a 200-day moving average of $6.14. Amyris, Inc. has a 52-week low of $0.21 and a 52-week high of $18.15.
In related news, Director Patrick Y. Yang acquired 300,000 shares of the firm’s stock in a transaction on Friday, May 19th. The stock was bought at an average price of $0.29 per share, for a total transaction of $87,000.00. Following the completion of the purchase, the director now directly owns 153,000 shares of the company’s stock, valued at approximately $44,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 11.30% of the company’s stock.
Several equities analysts recently commented on the company. Zacks Investment Research raised Amyris from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 16th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Amyris in a research note on Tuesday, May 23rd. Finally, ValuEngine downgraded shares of Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $31.13.
COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/03/amyris-inc-nasdaqamrs-set-to-announce-quarterly-earnings-on-thursday.html.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.